Journal of hepatocellular carcinoma · 2026
Nomogram Using Taurocholic Acid, Age, and Albumin to Predict HBV-Related Cirrhosis/HCC in CHB Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Xuemei, Zheng Liming, Zheng Wenlan, Shi Jia, Yu Shihan, Liu Hao, Feng Hai, Yu Zhuo
Аннотация
PURPOSE: Progression to liver cirrhosis (LC) and hepatocellular carcinoma (HCC) is a severe epidemiological risk factor for chronic hepatitis B (CHB); therefore, effective monitoring strategies are urgently required. Dysregulation of bile acids (BAs) metabolism is crucial for aggravating the pathological processes of liver diseases. In this study, we aimed to develop a risk model based on the BAs signature to predict the likelihood of LC and HCC occurrence in CHB patients.
PATIENTS AND METHODS: A retrospective analysis was conducted using the clinical data of 609 patients diagnosed with CHB, HBV-related LC, and HCC. Patients were randomly assigned to a training or validation set. Logistic regression analyses were employed in the training set to identify key variables and establish a nomogram risk model for predicting the progression of CHB to LC and HCC. Accuracy, calibration, and clinical utility of the model were assessed using a validation set.
RESULTS: Taurocholic acid level and age were independent risk factors, and serum albumin level was a protective factor against the progression of CHB to LC and HCC. A Nomogram risk model was developed using these three indicators, demonstrating a highly accurate and reliable ability to predict the progression from CHB to LC and HCC with good clinical validity and utility.
CONCLUSION: This study developed a nomogram incorporating BA markers, enabling precise prediction of LC and HCC in patients with CHB. This provided an accurate and accessible method for early screening and prevention.
PATIENTS AND METHODS: A retrospective analysis was conducted using the clinical data of 609 patients diagnosed with CHB, HBV-related LC, and HCC. Patients were randomly assigned to a training or validation set. Logistic regression analyses were employed in the training set to identify key variables and establish a nomogram risk model for predicting the progression of CHB to LC and HCC. Accuracy, calibration, and clinical utility of the model were assessed using a validation set.
RESULTS: Taurocholic acid level and age were independent risk factors, and serum albumin level was a protective factor against the progression of CHB to LC and HCC. A Nomogram risk model was developed using these three indicators, demonstrating a highly accurate and reliable ability to predict the progression from CHB to LC and HCC with good clinical validity and utility.
CONCLUSION: This study developed a nomogram incorporating BA markers, enabling precise prediction of LC and HCC in patients with CHB. This provided an accurate and accessible method for early screening and prevention.